Name (Synonyms) | Correlation | |
---|---|---|
drug2791 | Symptoms questionnare Wiki | 0.71 |
drug3263 | everolimus Wiki | 0.71 |
drug3325 | lulizumab pegol Wiki | 0.71 |
drug3341 | methylprednisolone Wiki | 0.71 |
drug1225 | Health Care Worker Survey Wiki | 0.71 |
drug3195 | belatacept Wiki | 0.71 |
drug3358 | mycophenolic acid Wiki | 0.71 |
drug3181 | antithymocyte globulin (rabbit) Wiki | 0.71 |
drug3356 | mycophenolate mofetil Wiki | 0.71 |
drug3498 | tocilizumab Wiki | 0.50 |
drug547 | COVID-19 RT-PCR Wiki | 0.41 |
drug2219 | Prednisone Wiki | 0.32 |
There are 2 clinical trials
The 2019-20 coronavirus disease, caused by COVID-19, is an ongoing pandemic. The measures in which public health officials quarantine confirmed and isolate symptomatic cases in order to reduce the spread COVID-19 is the common practice used in most countries. However, a significant question remains in regards to the asymptomatically infected individuals, which may propagate the virus and impede infection control. The other question to consider is whether these asymptomatic carriers develop an immune response or continue viral shedding. The purpose of the current study is the evaluate the immune response, i.e developing anti-SARS-CoV-2 antibodies in the asymptomatic cases, in a household study design. We plan to evaluate over 1000 patients with positive COVID-19 results and their households.
Description: The percentage of symptomatic patients who developed either IgM/IgG/IgA response within 100 days from COVID-19 Infection
Measure: Proportion of symptomatic patients with immune response (IgM/IgG/IgA) Time: 100 daysDescription: The percentage of Asymptomatic patients who developed either IgM/IgG/IgA response within 100 days from COVID-19 Infection
Measure: Proportion of Asymptomatic patients with immune response (IgM/IgG/IgA) Time: 100 daysDescription: the mean time patients devleoped IgM
Measure: Time to IgM Time: Evaluated within a 100 days followupDescription: the mean time patients devleoped IgG
Measure: Time to IgG Time: Evaluated within a 100 days followupDescription: the mean time patients devleoped IgG
Measure: Time to IgA Time: Evaluated within a 100 days followupDescription: Cohen's kappa coefficient calculated between the different serology kits used for evaluation
Measure: Serology kits inter-observer agreement Time: Evaluated within a 100 days followupThe novel coronavirus (SARS-CoV-2) has spread all around the world and testing has posed a challenge globally. Health care providers are highly exposed and are an important group to test. On top of these concerns, health care workers are also stressed by the needs on responders in the COVID-19 crisis. The investigators will look at different ways to measure how common COVID-19 is among health care workers, how common is the presence of antibodies by serological tests (also known as serostatus). The investigators will describe health worker mental and emotional well-being and their coping strategies in their institutional settings. Lastly, the investigators will describe how knowing serostatus can affect individuals' mental and emotional well-being and how to cope in the midst of the COVID-19 response. This will help to how to better test and help healthcare workers in the COVID-19 pandemic and prepare for possible future outbreaks.
Description: Percentage of health care workers with positive serological markers to describe patterns in exposure, re-infection, clinical symptom, serological responses among health care workers based on their baseline serological status over a one year period.
Measure: Proportion seropositive Time: Up to 12 months after collection visit